Invesco Ltd. Grows Stock Holdings in Humana Inc. (NYSE:HUM)

Invesco Ltd. grew its position in Humana Inc. (NYSE:HUM - Free Report) by 29.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,397,808 shares of the insurance provider's stock after purchasing an additional 550,692 shares during the period. Invesco Ltd. owned about 1.99% of Humana worth $608,348,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the company. FPC Investment Advisory Inc. bought a new position in shares of Humana during the 4th quarter worth approximately $27,000. Centricity Wealth Management LLC purchased a new stake in shares of Humana during the fourth quarter valued at approximately $30,000. LFA Lugano Financial Advisors SA lifted its holdings in Humana by 56.3% during the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock worth $32,000 after acquiring an additional 45 shares during the period. OFI Invest Asset Management bought a new position in Humana in the 4th quarter valued at $33,000. Finally, Atwood & Palmer Inc. increased its position in shares of Humana by 64.5% during the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider's stock valued at $39,000 after purchasing an additional 60 shares during the last quarter. 92.38% of the stock is owned by institutional investors.

Humana Price Performance

HUM traded up $4.72 during trading on Friday, reaching $294.97. The stock had a trading volume of 1,674,634 shares, compared to its average volume of 1,752,261. The business has a 50-day moving average of $265.55 and a 200-day moving average of $270.35. Humana Inc. has a one year low of $213.31 and a one year high of $406.46. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. The stock has a market cap of $35.60 billion, a PE ratio of 29.65, a PEG ratio of 2.05 and a beta of 0.62.

Remove Ads

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, equities research analysts anticipate that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a dividend of $0.885 per share. The ex-dividend date is Friday, March 28th. This represents a $3.54 annualized dividend and a yield of 1.20%. Humana's payout ratio is 35.58%.

Analyst Ratings Changes

HUM has been the subject of several research reports. Barclays increased their price target on shares of Humana from $270.00 to $322.00 and gave the company an "equal weight" rating in a research report on Friday. StockNews.com upgraded Humana from a "hold" rating to a "buy" rating in a research note on Monday, April 7th. JPMorgan Chase & Co. dropped their price target on Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 18th. Mizuho lifted their price objective on Humana from $305.00 to $316.00 and gave the stock an "outperform" rating in a report on Wednesday. Finally, Morgan Stanley cut their target price on shares of Humana from $301.00 to $285.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 12th. Seventeen analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $288.60.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.